InvestorsHub Logo
Followers 122
Posts 6384
Boards Moderated 0
Alias Born 08/17/2014

Re: iclight post# 31886

Friday, 03/27/2015 2:17:07 PM

Friday, March 27, 2015 2:17:07 PM

Post# of 694704
It's all relative iclight. You can't on one hand say they're not removing the sickest of the sick from their own Ph III, and then on the other day that they are. You can however discount their results to their comparative control arm if that's what you're meaning to imply. In my post, I was arguing that they gave us the data the best way they could. I made mention that it's information to me.

The only group that is a true value to me if any would be ePDs (psPD too small; undetermined too unclear if psPDs exist within that group, regardless that I suspect not). Rapids within any KPS survival timeline, immunotherapy appears to have extended that group by a wide margin. Now if you want to question whether that group is even the correct, that's fine. Simply pull out the only confirmed data points for the confirmed ePD and just compare those to any ePD patient, and you'll find that when the vaccine works well the results are unprecedented, and when it might not, the results may or may not follow the norm. After all we have no idea when those patients would have died without treatment, but we are pretty certain that none would be alive today without it. Why? Because there is a clear indication that no other treatment in the world has been able to produce a long tail survivor, let alone 2. Bottom line the information is telling us it works. And the Ph III is well on its way to prove it.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News